Mias Pharma
Mias Pharma is recorded as a service provider in 1 clinical trial. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 1 of 1 trials · Latest update first
TAZEMETOSTAT ROLLOVER STUDY (TRUST): AN OPEN-LABEL, ROLLOVER STUDY
Sponsor Epizyme Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available6 trial-level findings · Read insights
- The rollover study enrolled 58 participants across 30 centers in seven countries.
- Enrollment was restricted to participants from six antecedent tazemetostat studies who continued to benefit from treatment or were in overall-survival follow-up.
- A 2018 amendment added exclusions for thrombocytopenia, neutropenia, anemia, and prior myeloid malignancies.
- Safety monitoring was intensified through chest ultrasound at screening and every 12 weeks, blood-smear assessment with specified marrow and cytogenetic testing for abnormal results, and three-monthly complete blood count and blood-smear testing.
- Tumor assessments were revised to occur every 12 weeks.
- A 2021 amendment permitted participants in survival follow-up to roll over into EZH-501.
These findings describe the trial, not the service provider’s performance or responsibility.
Questions about this trial experience
What services are recorded for Mias Pharma?
The 2026-10-09 snapshot links Mias Pharma to 1 distinct CTIS trials. Recorded services include Medicinal product management. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Mias Pharma?
The most frequently recorded therapeutic areas are Gynecology, Haematological Malignancies, Solid Tumor Oncology, Urology. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Mias Pharma conducted?
The linked trials record locations in 2 countries, including France, Poland. These are trial locations, not confirmed office locations or countries where Mias Pharma delivered services.
What can this page tell me about Mias Pharma's trial experience?
Browse 1 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Mias Pharma. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Mias Pharma Limited